FDA批准阿斯利康的SGLT2抑制剂Farxiga,用于治疗射血分数降低的心力衰竭患者

2020-05-06 MedSci原创 MedSci原创

获得FDA批准后,Farxiga已成为美国第一个批准用于治疗HFrEF患者的SGLT2抑制剂。

美国FDA批准阿斯利康的钠葡萄糖共转运蛋白2(SGLT2)抑制剂Farxiga(dapagliflozin),用于降低患有或未患有II型糖尿病、射血分数降低的心力衰竭(HFrEF)成年患者的心血管疾病(CV)死亡和心力衰竭的住院风险。

批准基于具有里程碑意义的III阶段DAPA-HF试验的积极结果,该试验表明与安慰剂相比,该药物降低了CV死亡或心力衰竭恶化风险。

Farxiga于2019年9月获得FDA授予的快速通道称号,并在今年早些时候获得FDA授予的优先审查称号。

在2019年10月,FDA批准Farxiga用于降低患有II型糖尿病、存在CV疾病或多种CV危险因素的成年患者因心衰住院的风险。获得批准后,该药物现已成为该国第一个批准用于治疗HFrEF患者的SGLT2抑制剂。

英国格拉斯哥大学心血管与医学科学研究所心血管研究中心的John McMurray指出:"Farxiga为医师提供了一种新型治疗方法,可大大改善心力衰竭患者的射血分数。"

原始出处:

http://www.pharmatimes.com/news/us_oks_az_farxiga_for_heart_failure_with_reduced_ejection_fraction_1339866

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839810, encodeId=1f24183981072, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Nov 01 10:39:34 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793843, encodeId=b88f1e93843d1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue Jan 05 22:39:34 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995598, encodeId=960a1995598b5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Mar 30 20:39:34 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852360, encodeId=596c185236077, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 12 15:39:34 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257539, encodeId=67e2125e539a1, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449263, encodeId=e4041449263b9, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503801, encodeId=5d8e1503801e2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503946, encodeId=ce2f150394646, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533465, encodeId=ac8a15334653a, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16229, encryptionId=23be16229ce, topicName=SGLT2抑制剂Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7fa12453417, createdName=天堂的云, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-11-01 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839810, encodeId=1f24183981072, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Nov 01 10:39:34 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793843, encodeId=b88f1e93843d1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue Jan 05 22:39:34 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995598, encodeId=960a1995598b5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Mar 30 20:39:34 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852360, encodeId=596c185236077, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 12 15:39:34 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257539, encodeId=67e2125e539a1, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449263, encodeId=e4041449263b9, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503801, encodeId=5d8e1503801e2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503946, encodeId=ce2f150394646, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533465, encodeId=ac8a15334653a, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16229, encryptionId=23be16229ce, topicName=SGLT2抑制剂Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7fa12453417, createdName=天堂的云, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2021-01-05 tulenzi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839810, encodeId=1f24183981072, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Nov 01 10:39:34 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793843, encodeId=b88f1e93843d1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue Jan 05 22:39:34 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995598, encodeId=960a1995598b5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Mar 30 20:39:34 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852360, encodeId=596c185236077, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 12 15:39:34 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257539, encodeId=67e2125e539a1, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449263, encodeId=e4041449263b9, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503801, encodeId=5d8e1503801e2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503946, encodeId=ce2f150394646, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533465, encodeId=ac8a15334653a, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16229, encryptionId=23be16229ce, topicName=SGLT2抑制剂Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7fa12453417, createdName=天堂的云, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839810, encodeId=1f24183981072, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Nov 01 10:39:34 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793843, encodeId=b88f1e93843d1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue Jan 05 22:39:34 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995598, encodeId=960a1995598b5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Mar 30 20:39:34 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852360, encodeId=596c185236077, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 12 15:39:34 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257539, encodeId=67e2125e539a1, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449263, encodeId=e4041449263b9, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503801, encodeId=5d8e1503801e2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503946, encodeId=ce2f150394646, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533465, encodeId=ac8a15334653a, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16229, encryptionId=23be16229ce, topicName=SGLT2抑制剂Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7fa12453417, createdName=天堂的云, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2021-02-12 jklm09
  5. [GetPortalCommentsPageByObjectIdResponse(id=1839810, encodeId=1f24183981072, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Nov 01 10:39:34 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793843, encodeId=b88f1e93843d1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue Jan 05 22:39:34 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995598, encodeId=960a1995598b5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Mar 30 20:39:34 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852360, encodeId=596c185236077, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 12 15:39:34 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257539, encodeId=67e2125e539a1, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449263, encodeId=e4041449263b9, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503801, encodeId=5d8e1503801e2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503946, encodeId=ce2f150394646, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533465, encodeId=ac8a15334653a, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16229, encryptionId=23be16229ce, topicName=SGLT2抑制剂Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7fa12453417, createdName=天堂的云, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1839810, encodeId=1f24183981072, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Nov 01 10:39:34 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793843, encodeId=b88f1e93843d1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue Jan 05 22:39:34 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995598, encodeId=960a1995598b5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Mar 30 20:39:34 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852360, encodeId=596c185236077, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 12 15:39:34 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257539, encodeId=67e2125e539a1, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449263, encodeId=e4041449263b9, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503801, encodeId=5d8e1503801e2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503946, encodeId=ce2f150394646, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533465, encodeId=ac8a15334653a, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16229, encryptionId=23be16229ce, topicName=SGLT2抑制剂Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7fa12453417, createdName=天堂的云, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1839810, encodeId=1f24183981072, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Nov 01 10:39:34 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793843, encodeId=b88f1e93843d1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue Jan 05 22:39:34 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995598, encodeId=960a1995598b5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Mar 30 20:39:34 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852360, encodeId=596c185236077, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 12 15:39:34 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257539, encodeId=67e2125e539a1, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449263, encodeId=e4041449263b9, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503801, encodeId=5d8e1503801e2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503946, encodeId=ce2f150394646, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533465, encodeId=ac8a15334653a, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16229, encryptionId=23be16229ce, topicName=SGLT2抑制剂Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7fa12453417, createdName=天堂的云, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-08 jiekemin
  8. [GetPortalCommentsPageByObjectIdResponse(id=1839810, encodeId=1f24183981072, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Nov 01 10:39:34 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793843, encodeId=b88f1e93843d1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue Jan 05 22:39:34 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995598, encodeId=960a1995598b5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Mar 30 20:39:34 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852360, encodeId=596c185236077, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 12 15:39:34 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257539, encodeId=67e2125e539a1, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449263, encodeId=e4041449263b9, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503801, encodeId=5d8e1503801e2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503946, encodeId=ce2f150394646, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533465, encodeId=ac8a15334653a, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16229, encryptionId=23be16229ce, topicName=SGLT2抑制剂Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7fa12453417, createdName=天堂的云, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=)]
    2020-05-08 yibei
  9. [GetPortalCommentsPageByObjectIdResponse(id=1839810, encodeId=1f24183981072, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Nov 01 10:39:34 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793843, encodeId=b88f1e93843d1, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Tue Jan 05 22:39:34 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995598, encodeId=960a1995598b5, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Tue Mar 30 20:39:34 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852360, encodeId=596c185236077, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 12 15:39:34 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257539, encodeId=67e2125e539a1, content=<a href='/topic/show?id=b6b5e2474b' target=_blank style='color:#2F92EE;'>#Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7247, encryptionId=b6b5e2474b, topicName=Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449263, encodeId=e4041449263b9, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503801, encodeId=5d8e1503801e2, content=<a href='/topic/show?id=60b916226e1' target=_blank style='color:#2F92EE;'>#SGLT2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16226, encryptionId=60b916226e1, topicName=SGLT2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afa9693555, createdName=jiekemin, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503946, encodeId=ce2f150394646, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533465, encodeId=ac8a15334653a, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16229, encryptionId=23be16229ce, topicName=SGLT2抑制剂Farxiga)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7fa12453417, createdName=天堂的云, createdTime=Fri May 08 12:39:34 CST 2020, time=2020-05-08, status=1, ipAttribution=)]

相关资讯

Diabetes Care:血压变异性与心力衰竭风险

血压变异性与2型糖尿病患者的HF风险有关,这可能是舒张期缺血的结果。这些结果可能对优化2型糖尿病患者的血压治疗策略具有重要意义。

Sleep:自动正向气道压治疗可降低急性心力衰竭合并肺动脉高压和阻塞性睡眠呼吸暂停患者的肺部压力

肺动脉高压(PH)在急性失代偿性心力衰竭(ADHF)患者中极为常见,并预示着死亡率的增加。阻塞性睡眠呼吸暂停(OSA)在充血性心力衰竭患者中很常见,可能导致肺动脉高压进一步升高。本研究评估了正气道压(

ESC Heart Fail:射血分数保留和肺动脉高压的心衰患者弥漫性右心室纤维化情况

右心室(RV)功能障碍与合并病性肺动脉高压和伴有射血分数(PH-HFpEF)保留的心力衰竭不良预后有关,但尚不清楚导致RV功能障碍的机制。我们评估了PH-HFpEF中弥漫性RV心肌纤维化的程度和临床相

Cell Death Dis:PHB2缺乏会损害心脏脂肪酸氧化反应并导致心力衰竭

心力衰竭作为一种复杂的临床综合征,是现代社会发病率及死亡率的主要原因之一。心力衰竭的发病机制涉及多种机制,包括代谢紊乱、线粒体功能障碍、细胞自噬、细胞凋亡以及遗传或表观遗传的失调。心力衰竭潜在机制的研

JACC Heart Failure:心衰风险预测值男女有别,联合检测心脏生物标记物或能更早预测心衰发生

3月11日在线发表在《美国心脏病学会杂志·心力衰竭》(J Am Coll Cardiol HF)的一篇研究表明,高敏心肌肌钙蛋白I(hs-cTnI)是心力衰竭(HF)预后的独立预测因子

Circulation:常规进行心脏磁共振对特殊原因心衰患者病因诊断的作用

心脏磁共振(CMR)是一种被推荐用于心衰(HF)患者的影像学检查;但目前尚无证据显示CMR比经胸超声心动图更有益处。研究人员提出这样一个主要假设:常规使用CMR有助于精确诊断非缺血性心力衰竭;和一个次